# OnCo record folfirinox (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/folfirinox/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "folfirinox" ;
  schema:name "FOLFIRINOX / mFOLFIRINOX"@en ;
  schema:description "FOLFIRINOX is a four-drug chemotherapy combination that, in 2011, became the first treatment to meaningfully extend life in metastatic pancreatic cancer; it is now the standard before and after surgery."@en ;
  schema:url <https://onco.cc/drugs/folfirinox/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/FOLFIRINOX> ;
  owl:sameAs <http://www.wikidata.org/entity/Q17144959> ;
  schema:citation <https://en.wikipedia.org/wiki/FOLFIRINOX>, <https://www.nice.org.uk/guidance/ng85/chapter/Recommendations>, <https://doi.org/10.1056/NEJMoa1011923>, <https://doi.org/10.1001/jamaoncol.2022.3829> ;
  onco:status "standard-of-care" ;
  onco:modality "Cytotoxic regimen" ;
  onco:approval "Global 2011: Metastatic PDAC (PRODIGE 4 / ACCORD 11; component drugs generic)" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:trials <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/napoli-3/>, <https://onco.cc/trials/nct06922591/>, <https://onco.cc/trials/nct07255404/>, <https://onco.cc/trials/prodige-4-accord-11/>, <https://onco.cc/trials/preopanc-2/>, <https://onco.cc/trials/preopanc-3/>, <https://onco.cc/trials/alliance-a021806/>, <https://onco.cc/trials/alliance-a021501/>, <https://onco.cc/trials/swog-s1505/>, <https://onco.cc/trials/neolap/>, <https://onco.cc/trials/conko-007/>, <https://onco.cc/trials/panoptimox-prodige-35/>, <https://onco.cc/trials/crossfire/>, <https://onco.cc/trials/avenger-500/>, <https://onco.cc/trials/norpact-1/>, <https://onco.cc/trials/espac-5/> .